Showing results (471-480 of 525) with videos related to
Sort By:
Pageof 53
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.Journal of Virology|July 29, 2011
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestorsMattia Bonsignori, Kwan-Ki Hwang, Xi Chen, et al.Plos Medicine|June 24, 2024
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trialStephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.Journal of Medicinal Chemistry|June 6, 2013
Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infectionsThomas V Magee, Matthew F Brown, Jeremy T Starr, et al.Journal of Medicinal Chemistry|January 20, 2012
Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infectionsJustin I Montgomery, Matthew F Brown, Usa Reilly, et al.Plos One|April 27, 2018
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvantYingxia Wen, Hung V Trinh, Christine E Linton, et al.Nature Communications|June 9, 2017
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challengeTodd Bradley, Justin Pollara, Sampa Santra, et al.Nature|December 20, 2013
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIVMario Roederer, Brandon F Keele, Stephen D Schmidt, et al.Cell Reports|March 2, 2017
Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman PrimatesKevin O Saunders, Nathan I Nicely, Kevin Wiehe, et al.AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.Pageof 53